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Objective: After successful progestin therapy for endometrial hyperplasia (EH), the risk of 23 
relapse remains. We aimed to assess if immunohistochemical (IHC) expression of 24 
progesterone receptor isoforms, PR-A and PR-B, in endometrial glands and stroma in pre-25 
treatment endometrial biopsies were related to relapse of EH.  26 
Design and setting: Biopsy material originated from women with low- and medium-risk EH 27 
recruited to a recent Norwegian multicentre randomized trial. Participants (n=153) had been 28 
treated for six months with three different progestin regimes.  29 
Population: 135 of the 153 women achieved therapy response and underwent follow-up for 30 
24 months after therapy withdrawal. 55 women relapsed during follow-up. Pre-treatment 31 
endometrial biopsies from 94 of the 135 responding women were available for IHC staining. 32 
Methods: IHC staining was performed separately for PR-A and PR-B and IHC expression 33 
was evaluated in endometrial glands and stroma by a histological score (H-score) using light 34 
microscopy.  35 
Main Outcome Measure: IHC expression of PR-A and PR-B in endometrial glands and 36 
stroma in women with or without relapse of EH.    37 
Results: Low PR-A in endometrial glands (p=0.013) and stroma (p<0.001), and high PR-B in 38 
endometrial glands (p=0.001), in pre-treatment endometrial biopsy have a statistically 39 
significant association with relapse of EH. Women with a pre-treatment ratio of PR-A:PR-40 
B≤1 have higher risk of relapse (71%) compared to women with a ratio of PR-A:PR-B>1 41 
(19%) (p<0.001). 42 
Conclusion: IHC expression of PR-A and PR-B in pre-treatment endometrial biopsy proves 43 
valuable as predictors of relapse in EH. 44 
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Endometrial hyperplasia (EH) represents the preliminary stage of endometrial carcinoma 51 
(EC), and one in five cases will proceed to EC if left untreated.1 The pathogenesis of the 52 
disease is not fully understood but it is well known that continuous exposure to endogenous 53 
and exogenous estrogen, unopposed by progesterone, is important in development of EH, and 54 
eventually EC.2, 3 Progestin therapy has demonstrated a dose-dependent, curative effect on EH 55 
in former publications, the levonorgestrel impregnated intrauterine system (LNG-IUS) being 56 
superior to oral administration.4-10 Nevertheless, when therapy is discontinued, the risk of 57 
relapse of EH has proven independent on former progestin therapy regime.11 In different 58 
patient populations, the relapse rate after progestin withdrawal has been shown to vary 59 
between 13.7% to 41%.11, 12 60 
Progesterone’s growth inhibitory effects in the endometrial mucosa are mediated through 61 
interaction with nuclear progesterone receptors (PRs), acting as ligand-activated 62 
transcriptional factors and being members of the nuclear receptor superfamily.13 The two most 63 
studied isoforms, progesterone receptor A (PR-A) and progesterone receptor B (PR-B), are 64 
expressed in endometrial glands and stroma and expression of both are required to ensure 65 
normal endometrial differentiation.14 Alterations in the relative expression levels of PR-A and 66 
PR-B can result in aberrant PR signaling with altered gene transcription and such imbalance 67 
has been found in early carcinogenesis in hormone-sensitive cancer tissues.15, 16 Predominant 68 
expression of PR-A or PR-B can result from increased expression of one isoform, with or 69 
without loss of the other, or isolated loss of one isoform. 70 
The individual role of the PR-A and PR-B isoform in the etiology and prognosis of EH 71 
remains unclear, but a deregulation of PR-A and PR-B in either, or both, of the two 72 
endometrial tissue compartments (glands and stroma) is likely to be involved in disturbed 73 
endometrial proliferation through progression to EH, and EC. However, only a few studies 74 
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exist elucidating the prognostic significance of changes in endometrial expression of PR-A 75 
and PR-B for progestin responsiveness 17, 18 or relapse 19, 20 in EH.  76 
Our main objective for the present study was to investigate if pre-treatment 77 
immunohistochemical (IHC) expression of PR-A and PR-B, in endometrial biopsies from 94 78 
women diagnosed with low- to medium risk EH, are valuable as predictors for early relapse of 79 
EH after successful progestin therapy. An identification of reliable and feasible prognostic 80 
biomarkers in EH can provide for individualized therapy and follow-up strategies in women 81 




Trial design  84 
Endometrial biopsy material for the present study originated from women between 30 and 70 85 
years with histologically confirmed low- and medium-risk EH recruited to our national 86 
multicentre randomized trial.10 No patient and public involvement (PPI) was included in the 87 
design of that study as this process took place during 2002 – 2004, and no formalized 88 
requirement for PPI in research existed in our country at that time. Participating  women were 89 
treated for six months with either LNG-IUS 52 mg (Mirena®, Bayer Pharmaceuticals, Berlin, 90 
Germany), oral 10 mg Medroxyprogesterone acetate (MPA) daily or oral 10 mg MPA for 10 91 
days per cycle after written informed consent.10 The study inclusion period was from 1st of 92 
January 2005 to 1st of November 2011 and the treatment period was completed on 1st of May 93 
2012. After six months of treatment, all therapy were withdrawn. To monitor relapse, all 94 
patients with primary therapy response (n=135) underwent follow-up with endometrial 95 
resampling at six-month intervals for 24 months after therapy discontinuation.11  96 
The main outcome measure for the present study was defined as pre-treatment IHC expression 97 
of PR-A and PR-B in endometrial glands and stroma in women with or without relapse of EH. 98 
Core Outcome Sets (COS) have not yet been developed for EH and could therefore not be 99 
applied to our study. Histological material from 94 women with primary therapy response was 100 
available for IHC investigation with PR-A and PR-B. Insufficient biopsy material in the 101 
paraffin blocks was the reason for excluding 41 of the 135 women for the immunostaining 102 
procedure. Patient characteristics, such as age, WHO94 diagnosis, parity, BMI, menopausal 103 
status and serum estradiol level, were registered and the IHC expression of PR-A and PR-B in 104 
the pre-treatment endometrial biopsies were related to clinical relapse or not.   105 
Endometrial biopsy material  106 
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All endometrial biopsy material from each participant, pre-treatment (index), post-treatment 107 
(control) and follow-up biopsies, were obtained using an endometrial suction curette 108 
(Pipelle®, Laboratoire CCD, Paris, France). The endometrial biopsies were sent to the 109 
Department of Pathology at the University Hospital of North Norway for routine assessment. 110 
The specimens were fixed in buffered formaldehyde, embedded in paraffin and further 111 
processed in the laboratory before standard histological sections were made. A trained 112 
gynaecology pathologist (AO) and one additional routine pathologist, both of whom were 113 
blinded to each other’s diagnosis, performed diagnostic assessment of WHO94 classification 114 
by light microscopy. Agreement after discordant results was always obtained after discussion 115 
at a two-headed microscope. The index biopsies were classified into one of three groups: 116 
simple hyperplasia (SH), complex hyperplasia (CH), or atypical hyperplasia (AH) according 117 
to the WHO94 classification, which was considered the gold standard for evaluation of EH at 118 
the time the study was performed.1, 12 Normalized histology in the control biopsies after 119 
therapy were defined as ordinary proliferative endometrium or endometrium with progestin 120 
effect.1, 12 All information from the WHO classification of the index and control biopsies were 121 
registered and maintained in a separate database and subsequently supplemented by 122 
information from hospital records.   123 
Immunohistochemistry 124 
Immunohistochemistry was performed according to customer’s advice. Slides (with a 125 
thickness of 4-5 µm) were routinely cut from paraffin blocks and placed on 126 
Superfrost+glasses. Incubation overnight at 60°C followed. Deparaffinisation, pre-treatment 127 
(in Tris-based, slightly alkaline reagent (CC1) for 48 minutes at 95°C) and the staining were 128 
performed automatically in a Benchmark Ultra IHC/ISH staining module. Instrument and 129 
reagents were provided by Ventana Medical Systems Inc, USA. The first of the two primary 130 
antibodies used in the present study was the A-form of Progesterone Receptor, a monoclonal 131 
8 
 
IgG1 antibody. Clone 16, Novocastra, Leica Biosystems Newcastle Ltd, United Kingdom 132 
(PGR A). The initial total protein concentration was 5.1 g/L and the applied dilution 1/150 in 133 
Antibody Diluent (Ventana Medical Systems Inc. USA). The other primary antibody was the 134 
B-form of Progesterone Receptor, a monoclonal IgG1 antibody. Clone hPRa 2, Thermo Fisher 135 
Scientific, USA (PGR B). The initial protein concentration was 0.2 mg/mL and the applied 136 
dilution 1/150 in Antibody Diluent (Ventana Medical Systems Inc. USA). After addition of 137 
the primary antibody, slides were incubated for 60 minutes at 37°C.  Inhibitors were added to 138 
prevent nonspecific staining and enhancers were added to reinforce specific staining. 139 
Automatic DAB staining in several steps was performed before counterstaining with 140 
Hematoxylin. Ventana Medical Systems Inc, USA, provided the detection kits and all 141 
ancillaries used in this process. Slides were dehydrated and mounted before assessment. 142 
Interpretation of Immunohistochemistry 143 
Immunostaining for PR-A and PR-B were evaluated semi-quantitatively using an IHC 144 
histological score (H-score), which incorporates both the intensity and the distribution of 145 
specific staining. The H-score is defined as HS = ∑(Pi x i)/100, where Pi denotes the 146 
percentage of stained nuclei, and i denotes the intensity of staining ranging from 1 to 3.21 147 
Expression in the endometrial glands and stroma were evaluated separately for each 148 
specimen. Hot spots (areas with the strongest immunostaining) with a diameter of one cm 149 
were examined at 40 X magnification. Both the intensity of staining and the number of stain-150 
positive nuclei were counted. Samples with less than 10% positive nuclei were considered to 151 
be receptor-negative and given a score of zero. Samples with more than 10% positive nuclei 152 
were considered receptor-positive, and the percentage positive cells was used to compute the 153 
H-score. The H-score scale ranged from 0 to 3. A score of zero indicated the absence of 154 
staining, while scores of 1, 2 and 3 indicated weak, moderate and strong immunoreactivity, 155 
respectively. The H-score was assessed in a two-headed microscope by a trained 156 
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gynecological pathologist (AO) and a chief engineer (MA). Both investigators were blinded to 157 
the original diagnosis, therapy group and therapy response.  158 
Statistical methods 159 
Descriptive statistics are reported as mean and standard deviation or median and interquartile 160 
range for continuous variables based on the distribution of the variable, and as frequencies 161 
and percentages for categorical variables. Due to the binary outcome, relapse yes/no, 162 
univariable and multivariable logistic regression were performed with PR-A and PR-B in 163 
glands and stroma as independent variables. Univariable logistic regression was used to 164 
explore unadjusted effects, and multivariable logistic regression was used to adjust for clinical 165 
risk factors. PR-A in stroma and PR-A in glands could not be included in the same 166 
multivariable analysis due to high correlation. PR-A in stroma was chosen over PR-A in 167 
glands due to the lowest p-value in the univariable analysis. In addition, estradiol level is not 168 
included in the multivariable analyses due to high correlation with menopausal status. 169 
Continuous variables are categorized in the descriptive presentation, but are used as 170 
continuous in the regression analyses. Area under the curve (AUC) was calculated on a 171 
Receiver Operating Characteristic (ROC) curve. The diagnostic accuracy can generally be 172 
categorized as not useful for AUC<0.5, bad for AUC 0.5 – 0.6, sufficient for AUC 0.6 – 0.7, 173 
good for AUC 0.7 – 0.8, very good for AUC 0.8 – 0.9 and excellent for AUC 0.9 – 1.0.22 All 174 
statistical analyses were performed using IMB SPSS Statistics Version 24 (IMB Corp., 175 
Armonk, NY, USA), and a significance level of 0.05 was considered statistically significant.  176 
Funding  177 






Endometrial biopsies from 94 women with primary therapy response were 182 
immunohistochemically stained for PR-A and PR-B (Figure S1). Of these, 37 had been 183 
treated by LNG-IUS, 33 by oral 10 mg MPA daily and 24 by oral 10 mg MPA 10 days per 184 
cycle. In the present patient material 40 out of 94 women (43%) relapsed during 24 months 185 
follow-up, of which 80% were diagnosed with relapse during the first 12 months after therapy 186 
withdrawal. Demographic data related to relapse is outlined in Table 1. Women with relapse 187 
of EH were generally younger and had a higher median level of serum estradiol than women 188 
who did not relapse. The relapsing and non-relapsing women had about similar mean BMI, 189 
but a higher proportion of the relapsing women had BMI ≥ 26 (58% vs 45%). Atypical 190 
hyperplasia was more prevalent in the group of women with relapse compared to women with 191 
no relapse (15% vs 6%).  192 
PR-A and PR-B expression in endometrial glands and stroma in index biopsies related to 193 
relapse  194 
Mean H-score expression levels for PR-A and PR-B in endometrial glands and stroma for 195 
relapsing and non-relapsing women are presented in Figure 1. For PR-A, mean H-score 196 
expression was significantly lower in endometrial glands (p-value=0.013) and stroma (p-value 197 
<0.001) in women who experienced relapse of EH. Mean H-score expression of PR-B was 198 
significantly higher in endometrial glands (p-value=0.001) in relapsing women. The mean H-199 
score expression levels of PR-B in stroma did not differ significantly between relapsing and 200 
non-relapsing women (p-value=0.720). Figure S2 demonstrates an example of IHC staining 201 
intensity for PR-A and PR-B in endometrial glands and stroma in an index biopsy from one of 202 
the participating women.   203 
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The results of logistic regression univariable and multivariable analyses are presented in 204 
Table 2. Both PR-A in stroma and PR-B in glands remained statistically significant (p-205 
value<0.001, p-value=0.030) when adjusting for clinical risk factors (age, WHO94 diagnosis, 206 
BMI and menopausal status). Menopausal status and age were significantly associated to 207 
relapse in the univariable analyses, but their significance disappeared in the multivariable 208 
analysis. 209 
Subgroup analyses of PR-A and PR-B expression in endometrial glands and stroma in index 210 
biopsies related to relapse  211 
We performed subgroup analyses based on the three therapy groups. Due to small number of 212 
patients in each group, we only explored unadjusted effects of PR-A and PR-B expression in 213 
endometrial glands and stroma in index biopsies related to relapse of EH. In all three therapy 214 
groups pre-treatment expression pf PR-A in endometrial stroma was significantly associated 215 
to relapse (LNG-IUS: OR 0.21, 95% CI OR 0.07 – 0.63, p-value 0.006, oral 10 mg MPA 216 
daily: OR 0.10, 95% CI OR 0.02 – 0.60, p-value 0.012, oral 10 mg MPA 10 days per cycle: 217 
OR 0.14, 95% CI OR 0.03 – 0.73, p-value 0.020). Pre-treatment expression of PR-B in 218 
endometrial glands was significantly associated to relapse in women treated by LNG-IUS 219 
(OR 4.38, 95% CI OR 1.28 – 14.94, p-value 0.018) and oral 10 mg MPA 10 days per cycle 220 
(OR 8.30, 95% CI OR 1.47 – 47.00, p-value 0.017).  221 
Ratio of PR-A:PR-B expression in endometrial glands and stroma in index biopsies related to 222 
relapse 223 
We evaluated the unadjusted and adjusted effects of pre-treatment ratios of PR-A:PR-B 224 
related to relapse of EH (Table 3). A 0.1 unit increase in ratio of PR-A:PR-B in glands led to 225 
19% decreased odds for relapse, but the ratio of PR-A:PR-B in stroma did not have 226 
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statistically significant association with relapse. When combining glands+stroma for PR-A 227 
and PR-B a 0.1 unit increase in the ratio of PR-A:PR-B led to 17% decreased odds for relapse. 228 
A ROC-curve was calculated for the ratio of PR-A:PR-B (glands+stoma) and demonstrated  229 
AUC of 0.771 (p-value 0.000, 95% CI 0.67 – 0.87), indicating moderate diagnostic accuracy 230 
for prediction of relapse. A cut-off value of ≤1 gave sensitivity and specificity for prediction 231 
of relapse of 75% and 78%, respectively. Likelihood ratio for a positive test result was 3.4 and 232 
likelihood ratio for a negative test was 0.32. In the logistic regression analyses, a ratio of PR-233 
A:PR:B≤1 (glands+stoma) showed an 11-fold increased odds for relapse compared to PR-234 
A:PR-B>1 (Table 3). The cumulative relapse rates for women with a ratio of PR-A:PR-B≤1 235 
versus >1 were calculated to 71% and 19%.  236 
Discussion 237 
Main findings 238 
Until date, no reliable prognostic biomarkers have been found to predict relapse of EH to 239 
permit individualized long-term progestin therapy and follow-up. Our present results have 240 
demonstrated that low PR-A in endometrial glands and stroma, and high PR-B in endometrial 241 
glands, in pre-treatment endometrial biopsies are predictors of relapse after successful 242 
progestin therapy for EH. These results are in accordance with a recent publication reporting 243 
that low PR-A in endometrial stroma and high PR-B in endometrial glands prior to therapy 244 
correlated to relapse in EH in a retrospective study population.20 PR levels prior to therapy 245 
were reported only weakly associated with relapse in a study by Gallos and collaborators 246 
evaluating expression of estrogen receptor (ER), PR, COX-2, Mlh1 and Bcl-2 as predictors 247 
for relapse in women with EH.19 In contrast to our study, the expression of the two isoforms 248 
of PR were not separately reported.19  249 
Strengths and limitations 250 
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The strength of the current study relates to the origin of the endometrial biopsy material from 251 
a recent national multicenter randomized trial with 24 months follow-up. The IHC expression 252 
of both isoforms, PR-A and PR-B, were evaluated in individual tissue specimens and for each 253 
isoform endometrial glands and stroma were separately assessed. This permits for increased 254 
knowledge on isoform specific and tissue specific PR-signaling.  255 
A limitation is that our study participants had underwent progestin therapy in three different 256 
treatment arms and it can therefore be questioned if this has influenced our results. In the 257 
original publication, upon which the present study is based, relapse rates were shown to be 258 
independent on progestin regime. Additionally, our subgroup analyses demonstrated the same 259 
trend of pre-treatment expression of PR-A and PR-B in association to relapse as reported for 260 
the whole study population. Another limitation is the exclusion of 41 patients due to 261 
insufficient material in paraffin blocks. However, about similar number of patients were 262 
excluded from each therapy group. Finally, a comparison of our results to results from 263 
previous publications is not straight forward as Core Outcome Sets (COS) for literature 264 
reporting in EH has not yet been developed. This has led to great variations in e.g. progestin 265 
therapy regimes, therapy duration, follow-up duration after successful therapy, therapy 266 
withdrawal or not during follow-up, methods for endometrial resampling and 267 
histopathological diagnostic methods. However, work has begun to establish COS in EH and 268 
hopefully this will improve the use of consensus methodology in EH in the future.23  269 
Interpretation  270 
Our present findings indicate opposing actions for PR-A and PR-B in endometrial growth 271 
regulation. Potential physiological mechanisms underlying these observations are largely 272 
unknown, but different knockout mice models have been established to study individual PR 273 
isoform function in endometrial tissue.3, 24, 25 Data from these studies have revealed that PR-A 274 
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is essential for normal function of the endometrial epithelial glands and stroma, while PR-B 275 
promotes EH both in response to estrogen alone and to a combination of estrogen and 276 
progesterone.24 Further, in rat uterine cell studies PR-A has been found capable of inhibiting 277 
estrogen receptor (ER) activity.26 Thus, the PR-A isoform seems required to counteract both 278 
estrogen- and PR-B-induced proliferation. The applicability of these results to human 279 
endometrial tissue can clearly be discussed, but it implies that the relative balance of PR-A 280 
and PR-B is critical for the appropriate endometrial response to the hormonal environment.  281 
While PR-A and PR-B is co-expressed equivalent in the epithelial glands in the normal 282 
cycling endometrium, some have reported that PR-A is the predominant isoform in the 283 
stromal cells.27 It has recently been reported that the endometrial stroma creates a 284 
microenvironment that is decisive for progestin-responsiveness in the endometrial glands.3 285 
Thus, decreased stromal PR-A is suggested a main determinant to progestin resistance in EC 286 
cells.3 If such interactions between endometrial stromal and glandular cells is of importance in 287 
development of EH in humans remains unclear, but low stromal PR-A was the single 288 
predictor associated to relapse with lowest p-value (p-value<0.001) in our patient population. 289 
However, effective co-culture experiments using transformed human endometrial glandular 290 
and stromal cells are lacking to study interaction or mutual influence during carcinogenesis. 291 
The increasing understanding of PR-A and PR-B as distinct, and even contradictory, growth 292 
regulators has encouraged the exploration of the role of the relative expression of PR-A and 293 
PR-B in cancer types such as EC28 and breast cancer.29, 30 Jongen and colleagues found shorter 294 
disease free survival and shorter overall survival for EC patients with a ratio of PR-A:PR-295 
B<1. The results of the present study demonstrated an 11-fold increased odds for relapse in 296 
patients with pre-treatment PR-A:PR-B≤1 compared to patients with PR-A:PR-B>1. Thus, a 297 
pre-treatment ratio of PR-A:PR-B≤1 might represent a useful biomarker in clinical practice to 298 
select individuals with the highest risk of relapse. 299 
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In current EH management, the risk of relapse after successful progestin therapy has gained 300 
increasing attention. Progestin therapy duration for EH has traditionally been 3 – 6 months. 301 
Growing evidence has suggested that relapse of EH can be reduced, and probably avoided, as 302 
long as progestin therapy is continued. However, no tools to identify women who would 303 
benefit from long-term progestin treatment exist. To introduce prolonged progestin therapy 304 
for all women with EH is unwanted as such regime will represent over-treatment, and might 305 
cause unnecessary side effects, in a substantial number of patients. The present study indicates 306 
that the relative expression levels of PR-A and PR-B at the time of EH diagnosis can provide 307 
important information regarding probability for relapse. Thus, if our results can be confirmed 308 
in a larger population, these biomarkers can get implications for therapy duration, and 309 
surveillance frequency after progestin therapy withdrawal, on an individualized basis. IHC 310 
analyses of PR-A and PR-B are relatively feasible and low-cost procedures and can easily be 311 
implemented in routine EH diagnostics as adjuncts to standard microscopy and image 312 
analysis.  313 
Conclusion 314 
We have demonstrated that pre-treatment expression of PR-A in endometrial glands and 315 
stroma and PR-B in endometrial glands are valuable as predictors of relapse in EH and that 316 
low expression of PR-A to PR-B is associated with higher relapse rates. Increased knowledge 317 
of the two progesterone receptor isoforms actions might contribute to new diagnostic and 318 
therapeutical strategies in endometrial proliferative diseases. 319 
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Figure 1. Mean H-score expression levels of progesterone receptor isoforms, PR-A and PR-420 
B, in endometrial glands and stroma in index biopsies. The H-score scale range from 0 to 3. 421 
Results are presented as mean value ± Standard error of the mean. Univariable logistic 422 





Table 1. Demographic data for the study population related to relapse or no relapse of 426 








n=54, No Relapse 
n (%)  
Therapy regimen       
       LNG-IUS 
       MPA continuous 









Age (years), mean (SD) 
        < 43  
        43 – 48 
        49 – 51 











WHO94 classification            
       SH 
       CH 










       0-1 







Parity                 
       0-1 
       2 









BMI (kg/m2), mean (SD) 
       < 23 
       23 – 26 
       26 - 30 
       >30 










Menopausal statusǂǂ  
       Premenopausal 
       Perimenopausal 









Estradiol level (nmol/l), median (IQR) 
       ≤0.12 
        0.13 - 0.28 
        0.29 – 0.54 
        ≥ 0.55 










Abbreviations: LNG-IUS;Levonorgestrel impregnated system, MPA;Medroksypreogesterone acetate, SH;Simple 429 
hyperplasia, CH;Complex hyperplasia, AH;Atypical hyperplasia, SD;Standard deviation, IQR;Interquartile 430 
range.  431 
ǂ BMI value missing for 1 women. ǂǂ Menopausal status was defined according to s-estradiol (nmol/l) and s-FSH 432 
(IU/l) assessed before start of therapy. ǂǂǂ Estradiol level missing for 2 women.   433 
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Table 2. Unadjusted and adjusted effects of H-score expression levels of PR-A and PR-B 434 
related to relapse. PR-A stroma and PR-B glands were both included in the same 435 
multivariable analysis and adjusted for age, WHO94, BMI and menopausal status.  436 
 Unadjusted effects Adjusted effects 
Variable OR 95% CI OR p-value OR 95% CI OR p-value 
PR-A glands  0.39ǂ 0.19 – 0.83 0.013* -   
PR-A stroma 0.16ǂ 0.07 – 0.37 <0.001** 0.15ǂ 0.05 – 0.39 <0.001** 
PR-B glands  3.71ǂ 1.76 – 7.83 0.001** 2.91ǂ 1.11 – 7.62 0.030* 
PR-B stroma 1.13ǂ 0.57 – 2.24 0.720 -   
Age (years) 0.932 0.87 – 0.99 0.036* 1.05 0.95 – 1.16 0.336 
WHO94  
   SH  
   CH 







0.80 – 19.08 











1.06 – 60.62 





BMI (kg/m2) 1.03 0.95 – 1.10 0.507 1.10 0.99 – 1.22 0.090 
Menopausal status  
   Premenopausal  
   Perimenopausal 







0.08 – 0.61 











0.05 – 0.85 





Estradiol level (nmol/l) 1.81 0.77 – 4.28 0.174 -   
Abbreviations: OR;Odds ratio, CI;Confidence interval, SH;Simple hyperplasia, CH;Complex hyperplasia, 437 
AH;Atypical hyperplasia.  438 
ǂOdds ratios (OR) are shown for 1 unit increase in H-score levels for PR-A and PR-B. *p<0.05, **p<0.01. 439 
 440 
Table 3. Unadjusted and adjusted effects for H-score ratios of PR-A:PR-B related to relapse. 441 
Multivariable analyses were performed separately for each ratio with adjustment for age, 442 
WHO94, BMI and menopausal status. 443 
 Unadjusted effects Adjusted effects 
Variable OR 95% CI OR p-value OR 95% CI OR p-value 
Ratio PR-A glands : PR-B glands   0.81ǂ 0.72 – 0.90 <0.001** 0.80ǂ 0.69 – 0.92 0.002** 
Ratio PR-A stroma : PR-B stroma 0.97ǂ 0.92 – 1.01 0.143 0.98ǂ 0.93 – 1.02 0.253 
Ratio PR-A stroma : PR-B glands  0.78ǂ 0.69 – 0.87 <0.001** 0.76ǂ 0.67 – 0.87 <0.001** 
Ratio PR-A totalǂǂ : PR-B totalǂǂ 0.83ǂ 0.75 – 0.92 <0.001** 0.83ǂ 0.74 – 0.94 0.004** 
Ratio PR-A totalǂǂ : PR-B totalǂǂ ≤ 1 10.5 4.02 – 27.45 <0.001** 11.05 3.41 – 35.80 <0.001** 
Abbreviations: OR;Odds ratio, CI;Confidence interval. ǂOdds ratios (OR) are shown for 0.1 unit increase in ratio. 444 
ǂǂTotal means glands+stroma. *p<0.05, **p<0.01.  445 




Figure S1. Flowchart showing allocation, therapy response, relapse rates, and number of patients 448 
who had biopsies investigated by immunohistochemical staining of progesterone receptor A (PR-A) 449 
and progesterone receptor B (PR-B) in endometrial glands and stroma. A total of 41 patients were 450 
excluded before evaluation of PR-A and PR-B due to insufficient biopsy material in the paraffin 451 
blocks. Abbreviations: LNG-IUS;Levonorgestrel impregnated system, MPA;Medroksyprogesterone 452 
acetate 453 





Figure S2. Micrographs demonstrating immunohistochemical staining intensity for progesterone 457 
receptor A (PR-A) and progesterone receptor B (PR-B) in an index biopsy form a women diagnosed 458 
with CH. She obtained therapy response after six months of progestin therapy with LNG-IUS. She was 459 
later diagnosed with relapse 12 months after therapy withdrawal. Figure 2a and 2b represents 460 
endometrial glands and stroma, respectively, stained for PR-A. H-score level for PR-A was 1.1 in 461 
glands and 1.2 in stroma. Figure 2c and 2d is showing endometrial glands and stroma stained for PR-462 
B. H-score level for PR-B was 2.9 in glands and 2.9 in stroma. Abbreviations: CH;Complex hyperplasia, 463 
LNG-IUS;Levonorgestrel impregnated system  464 
 465 
2a 2b 
2c 2d 
